IMMUCELL CORP /DE/

ICCCSEC EDGAR

In Vitro & In Vivo Diagnostic Substances(DE)CIK: 811641

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	$18.6M	—	—	—
Cost of Goods and Services Sold	$13.6M	$10.9M	$10.6M	$8.5M	$7.0M
Gross Profit	$3.9M	$7.6M	$8.7M	$6.9M	$6.7M
Research and Development Expense	$4.4M	$4.5M	$4.2M	$4.4M	$3.7M
Operating Expenses	$9.6M	$9.9M	$8.4M	$8.2M	$7.7M
Operating Income (Loss)	-$5.7M	-$2.3M	$257.4K	-$1.4M	-$953.9K
Interest Expense	—	$348.5K	$314.4K	—	—
Nonoperating Income (Expense)	-$21.9K	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$43.8M	$44.9M	$44.5M	$40.3M	$38.7M
Assets, Current	$11.5M	—	$16.3M	$12.2M	$13.2M
Cash and Cash Equivalents, at Carrying Value	—	$5.8M	$10.2M	$6.9M	$6.3M
Accounts Receivable, after Allowance for Credit Loss, Current	$2.2M	$1.8M	$2.7M	$1.8M	$1.6M
Inventory, Net	$7.8M	$6.0M	$3.1M	$2.1M	$2.5M
Liabilities	$18.8M	$14.5M	$11.9M	$12.1M	$9.7M
Liabilities, Current	$4.2M	$3.1M	$2.5M	$2.2M	$2.5M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$4.7M	-$1.5M	$954.2K	$1.3M	$233.5K
Net Cash Provided by (Used in) Investing Activities	-$1.9M	-$4.0M	-$1.6M	-$2.6M	-$3.4M
Net Cash Provided by (Used in) Financing Activities	$1.8M	$1.1M	$3.9M	$1.9M	$6.9M
Payments to Acquire Property, Plant, and Equipment	$1.9M	$4.0M	$2.6M	$4.1M	$1.4M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)